Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated interferon alpha-2b + temozolomide
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
This is a combination therapy consisting of pegylated interferon alpha-2b (a long-acting, polyethylene glycol-conjugated form of recombinant human interferon alpha-2b) and temozolomide (an oral alkylating agent). Pegylated interferon alpha-2b acts as an immunomodulatory cytokine that stimulates the immune system to target tumor cells. Temozolomide is a DNA-methylating agent that induces cytotoxicity in rapidly dividing cancer cells by causing DNA damage and apoptosis. The combination has been investigated primarily for the treatment of advanced or metastatic melanoma and recurrent glioblastoma multiforme, with studies showing moderate antitumor activity and tolerability. The rationale for combining these agents is to leverage both direct cytotoxic effects on tumor cells (temozolomide) and immune-mediated antitumor activity (pegylated interferon alpha-2b)[1][6][9].
- Brand names
- Temodar + PEG-Intron
- Other names
- peg-IFNalpha-2b + temozolomidepeginterferon alfa-2b + temozolomidePEG IFN-alpha 2b + TMZ
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)DNA
Beyond the preview
Go deeper on pegylated interferon alpha-2b + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated interferon alpha-2b + temozolomide.